$RNA News

Atrium Therapeutics to Participate in Upcoming Investor Conferences

HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target

Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate

HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 Syndrome

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation

Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25

Atrium Therapeutics Reports First Quarter 2026 Financial Results

Atrium Therapeutics Q1 EPS $(0.97) Beats $(1.10) Estimate, Sales $19.635M Beat $2.000M Estimate

HC Wainwright & Co. Suspends Neutral Rating on Atrium Therapeutics

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion

Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline

Novartis acquisition spin-off pioneers RNA therapeutics for the heart

Wells Fargo Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies